Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
|ClinicalTrials.gov Identifier: NCT00429065|
Recruitment Status : Unknown
Verified January 2007 by Instituto Nacional de Cancerologia de Mexico.
Recruitment status was: Recruiting
First Posted : January 31, 2007
Last Update Posted : January 31, 2007
|Condition or disease||Intervention/treatment|
|Non-Hodgkin Lymphoma||Drug: Rituximab|
Treatment with rituximab and chemotherapy (R-CHOP)is the accepted treatment for young patients with diffuse large B cell Non-Hodgkin's Lymphoma. However not every patient benefits with this expensive therapy. Recent data suggest that patients with BCL-6 negative lymphoma are more sensitive to Rituximab therapy. It is also known that patients with high-intermediate and high IPI risk does not benefit form standard three weekly CHOP chemotherapy.
In this study we intend to define a subgroup of patients in whom this therapy will be of maximum benefit.
We will prospectively treat a group of patients with the following characteristics:
< 60 years old low and low intermediate IPI risk BCL-6 negative B-cell NHL Treatment regimen: R-CHOP (standard dosis) for 8 cycles
|Study Type :||Observational|
|Enrollment :||30 participants|
|Observational Model:||Defined Population|
|Official Title:||Selection of Young Patients (< 61 Years), With Good Prognosis Diffuse Large B Cell Lymphoma, According to the Immunophenotype (BCL-6 Negative) to be Treated With Chemoimmunotherapy, With R-CHOP. A Pilot Study.|
|Study Start Date :||January 2007|
|Study Completion Date :||January 2007|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00429065
|Contact: Silvia Rivas-Vera, MD||56 28 04 email@example.com|
|Contact: Pedro Sobrevilla-Calvo, MD||56 28 04 firstname.lastname@example.org|
|Instituto Nacional de Cancerologia||Recruiting|
|Mexico City, D.f., Mexico, 14080|
|Principal Investigator:||Pedro Sobrevilla-Calvo, MD||Instituto Nacional de Cancerologia Mexico|
|Principal Investigator:||Silvia Rivas-Vera, MD||Instituto Nacional de Cancerologia Mexico|